Thompson Siegel & Walmsley LLC Has $28.27 Million Stake in Teva Pharmaceutical Industries Limited (TEVA)

Thompson Siegel & Walmsley LLC cut its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 33.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,606,255 shares of the company’s stock after selling 816,227 shares during the quarter. Thompson Siegel & Walmsley LLC owned approximately 0.16% of Teva Pharmaceutical Industries Limited worth $28,270,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in TEVA. Capital Research Global Investors boosted its holdings in Teva Pharmaceutical Industries Limited by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after purchasing an additional 9,260,426 shares in the last quarter. Franklin Resources Inc. lifted its stake in Teva Pharmaceutical Industries Limited by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after buying an additional 6,685,844 shares during the last quarter. FMR LLC lifted its stake in Teva Pharmaceutical Industries Limited by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after buying an additional 6,115,853 shares during the last quarter. Northern Cross LLC lifted its stake in Teva Pharmaceutical Industries Limited by 14.0% in the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after buying an additional 2,184,172 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in Teva Pharmaceutical Industries Limited by 2.5% in the second quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock valued at $428,033,000 after buying an additional 311,894 shares during the last quarter. 52.29% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://stocknewstimes.com/2017/11/22/thompson-siegel-walmsley-llc-has-28-27-million-stake-in-teva-pharmaceutical-industries-limited-teva.html.

A number of equities research analysts have weighed in on the company. Credit Suisse Group reiterated an “underperform” rating and issued a $8.00 price objective (down previously from $14.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, November 6th. Royal Bank Of Canada reduced their price objective on Teva Pharmaceutical Industries Limited from $21.00 to $15.00 and set an “underperform” rating for the company in a research note on Monday, September 18th. Wells Fargo & Company reiterated a “market perform” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, October 5th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Sunday, November 12th. Finally, Maxim Group restated a “hold” rating and set a $15.50 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, September 14th. Seven analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries Limited has a consensus rating of “Hold” and an average price target of $21.88.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up $0.27 during trading hours on Wednesday, hitting $13.60. The company had a trading volume of 2,930,341 shares, compared to its average volume of 15,453,753. The stock has a market cap of $13,300.00, a P/E ratio of 3.02 and a beta of 0.52. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries Limited has a 1-year low of $10.85 and a 1-year high of $38.69.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be issued a dividend of $0.085 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $0.34 annualized dividend and a dividend yield of 2.50%. Teva Pharmaceutical Industries Limited’s payout ratio is currently -16.01%.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply